FDA warns Native Salts LLC over unapproved, misbranded ammonia smelling-salt stimulant sold as 'N, Native Salts'.
What happened
FDA reviewed the company website on November 15, 2023, and social media pages that direct consumers to the website. FDA found 'N, Native Salts' promoted as an OTC stimulant and smelling salt for alertness, energy, and focus, containing ammonium, eucalyptus oil, peppermint oil, polymer crystals, glycerin, and water. FDA says the product is an unapproved new drug and is misbranded.
What FDA found
The product is intended as a stimulant drug but has no FDA-approved new drug application.
FD&C Act section 505(a), 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug that does not meet section 505G requirements and has no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)Marketed as a reflex stimulant or smelling salt with ammonia, the product is deemed not generally recognized as safe and effective under FDA's most recent applicable proposed rule.
FD&C Act section 505G(a)(4), 21 U.S.C. 355h(a)(4)Even as a general stimulant, the product does not meet OTC Monograph M011 because ammonium is not an allowed active ingredient and the label gives intranasal directions.
FD&C Act section 505G, 21 U.S.C. 355h; OTC Monograph M011 (OTC000025)Introducing or delivering the product into interstate commerce is prohibited because it is an unapproved and misbranded drug.
FD&C Act sections 301(a) and 301(d), 21 U.S.C. 331(a) and 331(d)
What FDA wants
FDA tells the company to notify it in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence, with related documentation. If the company believes the products are not in violation, it must include its reasoning and supporting information.
Who should pay attention
- retailers and online marketplaces selling smelling salts or stimulant products
- brands marketing ammonia inhalants as OTC stimulants
- suppliers or contract manufacturers of ammonia-based consumer products
This is a summary. Read the original letter on fda.gov.